Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127225 | 0.87 | CYP17A1 (0.57) | CYP17A1DRD2PTGDR2MAPK14GLS | |
| SCHEMBL132701 | 0.86 | CYP17A1 (0.76) | CYP17A1DRD2PTGDR2MAPK14GLS | |
| SCHEMBL13055402 | 0.86 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL10361607 | 0.85 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL6195004 | 0.85 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14GLS | |
| SCHEMBL245094 | 0.85 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14GLS | |
| SCHEMBL6407210 | 0.84 | CYP17A1 (0.54) | CYP17A1DRD2PTGDR2MAPK14GLS | |
| SCHEMBL7079572 | 0.83 | CYP17A1 (0.52) | CYP17A1DRD2PTGDR2MAPK14GLS | |
| SCHEMBL15858111 | 0.83 | CYP17A1 (0.46) | CYP17A1DRD2PTGDR2MAPK14GLS | |
| SCHEMBL243856 | 0.83 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | GERO THOMAS (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4053108-B1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055063-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX BV (NL) | 2026-01-22 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12503444-B2 | Compound containing benzene ring and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4658318-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| WO-2011100829-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. (CA) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011100829-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. (CA) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010132982-A1 | TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2010-11-25 | — | — | WO | disclosed |
| US-20060100226-A1 | 2-Thiopyrimidinones as therapeutic agents | ATHEROGENICS, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006031806-A2 | 2-THIOPYRIMIDINONES AS THERAPEUTIC AGENTS | ATHEROGENICS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-6680312-B2 | FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403595-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1054005-A1 | SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
| EP-0589201-A1 | Di- and triazindeones | MERCK PATENT GmbH (DE) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055063-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | CNR2, RYR2, CNR1 | CYP17A1 657/4885DRD2 1817/4885PTGDR2 262/4885 |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | FCGR2A, FCGR3B, FCGR1A | CYP17A1 1052/4885DRD2 245/4885PTGDR2 3244/4885 |
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | ARAF, BRAF, RAF1 | CYP17A1 4431/4885DRD2 4001/4885PTGDR2 3557/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | CYP17A1 2650/4885DRD2 3318/4885PTGDR2 3582/4885 |
| US-20060100226-A1 | 2-Thiopyrimidinones as therapeutic agents | MAP3K6, MAP3K20, MAP3K7 | CYP17A1 2399/4885DRD2 4857/4885PTGDR2 964/4885 |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | F12, F11, F2 | CYP17A1 575/4885DRD2 1934/4885PTGDR2 1353/4885 |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | CYP17A1 3818/4885DRD2 2468/4885PTGDR2 895/4885 |
| US-12503444-B2 | Compound containing benzene ring and application thereof | P2RX4, P2RX7, P2RX2 | CYP17A1 667/4885DRD2 2674/4885PTGDR2 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.